Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Breast Carcinoma|HER-2 Positive Breast Cancer
Interventions: DRUG: Ruxolitinib|DRUG: Trastuzumab
Sponsor: Dawn L. Hershman
Collaborators: Incyte Corporation|National Cancer Institute (NCI)